All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Butyrate is a short chain fatty acid and represents a preferred energy source for the gut epithelium; it is also a histone deacetylase inhibitor and agonist for peroxisome proliferator-activated receptors. Butyrate is secreted by butyrogenic bacteria and its administration, in mice, after allogeneic hematopoietic cell transplant (allo-HCT) improved intestinal epithelial cells junctional integrity and decreased apoptosis and the severity of graft-versus-host disease (GvHD), suggesting that microbial metabolites can mitigate GvHD.1
In this paper, Jonathan L. Golob, Division of Infectious Diseases, Department of Medicine, University of Michigan, Ann Arbor, MI, and colleagues investigated the role of butyrogenic organisms in the development of steroid-refractory acute GvHD (SR-aGvHD), associated with high morbidity and mortality, or chronic GvHD (cGvHD) of the gut.2 Although butyrate has positive effects on the gut, its presence in the context of colitis inhibits healing of the murine gut.3 Thus, response to butyrate could be helpful or harmful in relation to the status of the colonic mucosa.
Study design and patients2
Results2
Conclusion
Butyrate is helpful in prevention of aGvHD1 but its presence after the onset of severe aGvHD of the gut affects the formation of a tight epithelial and impairs colonic mucosal recovery from aGvHD.2 Thus, once aGvHD has started, butyrogens may lead to increased risk for SR-aGvHD and potentially cGvHD.2 Therefore, microbiota-derived metabolites that are beneficial in health can lead to worsened outcomes after the onset of the disease. However, a butyrogen in the stool can be inactive and carefully preserved specimens are required to measure butyrate levels.
Your opinion matters
Subscribe to get the best content related to GvHD delivered to your inbox